President Donald Trump signed an executive order in the Oval Office on April 18, 2026, directing the FDA to fast-track psychedelic drugs like psilocybin and ibogaine for treating PTSD and depression in veterans.
The order mandates priority review through breakthrough therapy designations, priority vouchers, and expanded Right to Try access. It targets therapies for the roughly 6,000 veteran suicides each year and the 14 million U.S. adults battling severe depression.
Attendees included FDA Commissioner Marty Makary, Health Secretary Robert F. Kennedy Jr., podcaster Joe Rogan, and former Navy SEAL Marcus Luttrell. The White House ceremony underscored the push amid a national mental health crisis.
The order allocates at least $50 million from existing HHS funds for state partnerships, clinical trials, and data sharing with the Department of Veterans Affairs. FDA officials plan to issue priority vouchers for three psychedelics next week, paving the way for the first U.S. human trials of ibogaine.
“Today’s order will ensure that people suffering from debilitating symptoms might finally have a chance to reclaim their lives and lead a happier life,” President Donald Trump said.
Trump made the remarks during the signing, emphasizing rapid access to promising treatments. The directive also instructs the DEA and HHS to streamline research barriers for psychedelics.
Marcus Luttrell, a decorated veteran and author of Lone Survivor, attended and shared his personal experience.
FDA Commissioner Marty Makary, appointed earlier this year, welcomed the move. Speaking to reporters outside the White House in Washington, D.C., Marty Makary said the agency would expedite reviews without compromising safety standards. He noted psilocybin's Phase 3 trial success rates exceeding 70% for treatment-resistant depression.
Robert F. Kennedy Jr., HHS Secretary, highlighted veteran-specific needs. In a statement, Robert F. Kennedy Jr. pointed to VA data showing PTSD affects over 20% of post-9/11 veterans. The $50 million will fund partnerships with states like Oregon and Colorado, which have decriminalized psychedelics.
Joe Rogan, a vocal advocate for psychedelic research, joined the signing. Rogan has hosted numerous experts on his podcast discussing ibogaine's potential to curb opioid addiction and PTSD. Joe Rogan told CNBC the order represents a "paradigm shift" in federal policy.
Congressional reactions split along partisan lines. Rep. Marjorie Taylor Greene (R-GA) praised the order on X, calling it a win for veterans. Sen. Elizabeth Warren (D-MA) expressed caution, urging rigorous FDA oversight to prevent abuse.
- Fast-track psilocybin, ibogaine, and one additional psychedelic via FDA priority vouchers.
- $50 million for trials, state programs, VA data integration.
- DEA review of scheduling for research exemptions.
- Right to Try expansion for terminal illness-related mental health cases.
Veterans' groups responded positively. American Legion National Commander James Lachance called it a "lifeline" in a statement. The DAV echoed support, citing stalled VA psychedelic pilots.
Critics, including the Drug Policy Alliance, worry about commercialization. Executive Director Kassandra Frederique told NPR the order favors Big Pharma over community-based healing centers. Kassandra Frederique called for equitable access provisions.
Dr. Matthew Johnson, Johns Hopkins psychedelics researcher, offered measured optimism. In a CNBC interview, Dr. Matthew Johnson said, "Breakthrough status could shave years off approval timelines, but we need long-term data." His team published a 2025 study showing ibogaine reduced PTSD symptoms by 88% in small cohorts.
The order builds on Trump's first-term Right to Try law and Biden-era FDA nods to MDMA for PTSD, which stalled in 2024. HHS will report progress quarterly to Congress.
In the Oval Office, Trump shook hands with Luttrell after the signing. The room buzzed with attendees reviewing the 12-page document, which spans FDA, DEA, HHS, and VA coordination.
Psilocybin, derived from magic mushrooms, has shown promise in trials at institutions like UCSF and NYU. Ibogaine, from African iboga root, targets addiction but carries cardiac risks, prompting FDA caution.
| Psychedelic | Target Conditions |
| Psilocybin | PTSD, Depression |
| Ibogaine | PTSD, Opioid Addiction |
| Third (TBD) | Veteran Mental Health |
| Funding | $50 Million |
Implementation starts immediately, with FDA voucher announcements expected by April 25, 2026. States must apply for grants by June 1.
This move positions the U.S. alongside Canada and Australia in psychedelic medicine, potentially reshaping VA care for millions.
